David Debruyn Email & Phone Number

Benelux

Independent consultancy to broaden scope beyond pharmaceuticals-involved in government forming and the 7 year plan for social security both on federal level (Social Security, Sick funds, Verzekeringscomité)-outlaying all the plans for the Flemish region, amounting up to 1.1B€ in non-medical care. The biggest investment up to date in mental wellbeing, ageing and people struck with disabilities. -Strategic Advisor and implementation team lead to one of the Boards during the merger of Benelux’s biggest hospital for a smooth integration and detection of inefficiencies. E.g. capacity planning for geo-optimisation, offering expertise of 2 centres. Successfully convinced medical council they are also winning. -Smaller assignments rond EU HTA, evidence delivery plan, strategic pricing

Benelux

Responsible for optimizing access for the full company portfolio:- defending / renegotiating in line products approaching LoE such as blockbusters Xospata (AML), Evrenzo (CKD) and Xtandi (Pr. C). -while leading the pre launch teams to prepare the launches for exciting new compounds such as Padcev, Vyloy, and fenolinezetant.

Brussels Region, Belgium

• Development of both pricing and reimbursement files (Class I, Class II, art.59) in (hemato-)oncology, orphan and respiratory • Procedure follow up: responding to payer evaluation reports (FOD Economy, Day 60, 120, Day 150, MEA agreements) • Day-to-day responsibilities: project management with external vendors (medical writer, local adaptation of BIMs and C-E models), internal collaboration to develop the reimbursement strategy, co-create dossiers and deliver competitive insights, external focus with key stakeholders (payer, patient organisations, local KEEs that validate your positioning, target population and budget impact financials) Contract resubmissions and negotiations with authorities, budget impact models

Belgium

• Responsible for the Myeloid portfolio (>50% future revenues)• Manages 2 out of 5 in-market assets (forecasting, creation of new materials for field force, lifecycle management strategies, LoE defense)• Project management of 20 transversal projects aimed at supporting haematologists, pharmacists, nurses and patients • Overall responsibilities: Disease plan building and implementing the tactics, pre-launch, forecasting, OpEx planning, organising local congresses and AdBoards, insights gathering with KOLs, market research, creation of promotional materials to support field force.

Amsterdam, Germany, Israel. Belgium

Elite taskforce (2 / 1400 accepted Europe-wide) with 4 assignments across different businesses and locations: European Pricing & Market Access - EU HQ Amsterdam ▪ European tender strategy and biosimilar defences with different gross-to-net implications for a 5B$ blockbuster reaching LoE ▪ Development of pricing strategy and launch sequence for new products & price erosion analyses (International Price Referencing) ▪ Monitoring supply chain integrity, development of payer deliverables for local markets Gx Portfolio Value Optimisation - Ulm, Germany ▪ Tail Portfolio streamlining reducing low profitability SKUs => RA savings, operational cost reductions (impact: ~15% of global volume) ▪ Initiated operational improvements on top 50 Gx products: manufacturing footprint optimisation such as site harmonisations, divestitures, cheaper API sourcing, dual sourcing, make vs. buy considerations, and other BD projects with CMOs Strategic Projects & Alliances - Global HQ, Israel: internal management consulting team reporting directly to the CEO ▪ Gross-to-net optimisation for various European/Asian markets (in all 3 market types: Branded Gx, Pharmacy-driven and INN/tender) ▪ Key Account Management: global collaboration with different Pan-European wholesalers/retailers, each >2B$ in gross sales ▪ Restructuring & integration projects: 40 plant closures, headcount reduction of 60%~ 55.000 employees affected, divestments, P&L analysis and savings tracking Salesforce Effectiveness and organizational restructuring - Belgian market ▪ Field experience (both representative as co-sales manager) to understand the different customers, 2 sales teams and market dynamics ▪ Development and implementation of a customer segmentation and targeting —> new sectorisation, call plan and redundancies ▪ Sold our JV stake with P&G, Works Council negotiations since headcount -60% ▪Management buy out from

Europe

1) vendor due diligence of a PE-owned anti-biotics production sites2) top line growth programme and portfolio rationalisation for a top 5 FMCG leader.

London Area, United Kingdom

Traditional investment banking internship: assisted on a carve out of a 50B+ revenue generating listed company.